Non-Insulin Therapies for Diabetes Market Report

Europe Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 10, 2020
  • PAGES：211
  • REPORT CODE：GMM541753
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Non-Insulin Therapies for Diabetes market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.4% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Non-Insulin Therapies for Diabetes Market Segmentations:

    By Player:

    • Jiangsu Hengrui Medicine

    • Alkem Labs

    • GSK

    • Servier

    • Geropharm

    • Sumitomo Dainippon Pharma

    • Novo Nordisk

    • Takeda

    • Uni-Bio Science Group

    • Merck

    • Emisphere

    • Intarcia Therapeutics

    • Eli Lilly

    • 3SBio

    • Luye Pharma Group

    • SatRx

    • Dong-A Pharmaceutical

    • Jiangsu Hansoh Pharmaceutical

    • Eurofarma

    • Pfizer

    By Type:

    • Alpha-glucosidase Inhibitors

    • Amylin Agonists

    • Biguanides

    • Dipeptidyl Peptidase-4 (DPP4) Inhibitors

    • Glinides / Meglitinides

    • GLP-1 Analogs / GLP-1 Agonists

    • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

    • Sulfonylureas

    • Thiazolidinediones

    • Others

    By End-User:

    • Hospital Pharmacy

    • Retail Pharmacies

    • Online Pharmacy

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Non-Insulin Therapies for Diabetes Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Alpha-glucosidase Inhibitors from 2014 to 2026

    • 1.3.2 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Amylin Agonists from 2014 to 2026

    • 1.3.3 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Biguanides from 2014 to 2026

    • 1.3.4 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors from 2014 to 2026

    • 1.3.5 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Glinides / Meglitinides from 2014 to 2026

    • 1.3.6 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists from 2014 to 2026

    • 1.3.7 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors from 2014 to 2026

    • 1.3.8 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sulfonylureas from 2014 to 2026

    • 1.3.9 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Thiazolidinediones from 2014 to 2026

    • 1.3.10 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Hospital Pharmacy from 2014 to 2026

    • 1.4.2 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • 1.4.3 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Online Pharmacy from 2014 to 2026

    • 1.4.4 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Non-Insulin Therapies for Diabetes Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Non-Insulin Therapies for Diabetes by Major Types

      • 3.4.1 Market Size and Growth Rate of Alpha-glucosidase Inhibitors

      • 3.4.2 Market Size and Growth Rate of Amylin Agonists

      • 3.4.3 Market Size and Growth Rate of Biguanides

      • 3.4.4 Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors

      • 3.4.5 Market Size and Growth Rate of Glinides / Meglitinides

      • 3.4.6 Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists

      • 3.4.7 Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

      • 3.4.8 Market Size and Growth Rate of Sulfonylureas

      • 3.4.9 Market Size and Growth Rate of Thiazolidinediones

      • 3.4.10 Market Size and Growth Rate of Others

    4 Segmentation of Non-Insulin Therapies for Diabetes Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Non-Insulin Therapies for Diabetes by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospital Pharmacy for Construction

      • 4.4.2 Market Size and Growth Rate of Retail Pharmacies for Construction

      • 4.4.3 Market Size and Growth Rate of Online Pharmacy for Construction

      • 4.4.4 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Non-Insulin Therapies for Diabetes Production Analysis by Top Regions

    • 5.2 Europe Non-Insulin Therapies for Diabetes Consumption Analysis by Top Regions

    • 5.3 Europe Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.3 France Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    6 Product Circulation of Non-Insulin Therapies for Diabetes Market among Top Countries

    • 6.1 Top 5 Export Countries in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Non-Insulin Therapies for Diabetes Landscape Analysis

    • 7.1 Germany Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 7.2 Germany Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    8. UK Non-Insulin Therapies for Diabetes Landscape Analysis

    • 8.1 UK Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 8.2 UK Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    9. France Non-Insulin Therapies for Diabetes Landscape Analysis

    • 9.1 France Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 9.2 France Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    10. Italy Non-Insulin Therapies for Diabetes Landscape Analysis

    • 10.1 Italy Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 10.2 Italy Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    11. Spain Non-Insulin Therapies for Diabetes Landscape Analysis

    • 11.1 Spain Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 11.2 Spain Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    12. Poland Non-Insulin Therapies for Diabetes Landscape Analysis

    • 12.1 Poland Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 12.2 Poland Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    13. Russia Non-Insulin Therapies for Diabetes Landscape Analysis

    • 13.1 Russia Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 13.2 Russia Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    14. Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis

    • 14.1 Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 14.2 Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    15. Turkey Non-Insulin Therapies for Diabetes Landscape Analysis

    • 15.1 Turkey Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 15.2 Turkey Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 16.3.1 Denmark Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.2 Finland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.3 Norway Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.4 Sweden Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.6 Iceland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 17.3.1 Belgium Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 17.3.2 Netherlands Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 17.3.3 Luxembourg Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 18.3.1 Estonia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 18.3.2 Latvia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 18.3.3 Lithuania Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Jiangsu Hengrui Medicine

      • 19.1.1 Jiangsu Hengrui Medicine Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Alkem Labs

      • 19.2.1 Alkem Labs Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 GSK

      • 19.3.1 GSK Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Servier

      • 19.4.1 Servier Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Geropharm

      • 19.5.1 Geropharm Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sumitomo Dainippon Pharma

      • 19.6.1 Sumitomo Dainippon Pharma Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Novo Nordisk

      • 19.7.1 Novo Nordisk Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Takeda

      • 19.8.1 Takeda Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Uni-Bio Science Group

      • 19.9.1 Uni-Bio Science Group Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Merck

      • 19.10.1 Merck Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Emisphere

      • 19.11.1 Emisphere Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Intarcia Therapeutics

      • 19.12.1 Intarcia Therapeutics Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Eli Lilly

      • 19.13.1 Eli Lilly Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 3SBio

      • 19.14.1 3SBio Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Luye Pharma Group

      • 19.15.1 Luye Pharma Group Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 SatRx

      • 19.16.1 SatRx Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Dong-A Pharmaceutical

      • 19.17.1 Dong-A Pharmaceutical Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Jiangsu Hansoh Pharmaceutical

      • 19.18.1 Jiangsu Hansoh Pharmaceutical Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Eurofarma

      • 19.19.1 Eurofarma Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Pfizer

      • 19.20.1 Pfizer Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 106 Figures and 160 Tables)

    • Figure Product Picture

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Alpha-glucosidase Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Amylin Agonists Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Biguanides Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Glinides / Meglitinides Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sulfonylureas Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Thiazolidinediones Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Hospital Pharmacy from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Online Pharmacy from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure UK Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure France Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Non-Insulin Therapies for Diabetes Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Non-Insulin Therapies for Diabetes

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Non-Insulin Therapies for Diabetes by Different Types from 2014 to 2026

    • Table Consumption Share of Non-Insulin Therapies for Diabetes by Different Types from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Alpha-glucosidase Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Amylin Agonists Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Biguanides Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Glinides / Meglitinides Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sulfonylureas Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Thiazolidinediones Market, 2015 - 2026 (USD Million)

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Non-Insulin Therapies for Diabetes by Different End-Users from 2014 to 2026

    • Table Consumption Share of Non-Insulin Therapies for Diabetes by Different End-Users from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Hospital Pharmacy from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Online Pharmacy from 2014 to 2026

    • Figure Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Non-Insulin Therapies for Diabetes Production by Major Regions

    • Table Europe Non-Insulin Therapies for Diabetes Production Share by Major Regions

    • Figure Europe Non-Insulin Therapies for Diabetes Production Share by Major Countries and Regions in 2014

    • Table Europe Non-Insulin Therapies for Diabetes Consumption by Major Regions

    • Table Europe Non-Insulin Therapies for Diabetes Consumption Share by Major Regions

    • Table Germany Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table UK Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table France Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Italy Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Spain Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Poland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Russia Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Switzerland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Turkey Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Jiangsu Hengrui Medicine Profiles

    • Table Jiangsu Hengrui Medicine Production, Value, Price, Gross Margin 2014-2019

    • Table Jiangsu Hengrui Medicine Product benchmarking

    • Table Jiangsu Hengrui Medicine Strategic initiatives

    • Table Jiangsu Hengrui Medicine SWOT analysis

    • Table Alkem Labs Profiles

    • Table Alkem Labs Production, Value, Price, Gross Margin 2014-2019

    • Table Alkem Labs Product benchmarking

    • Table Alkem Labs Strategic initiatives

    • Table Alkem Labs SWOT analysis

    • Table GSK Profiles

    • Table GSK Production, Value, Price, Gross Margin 2014-2019

    • Table GSK Product benchmarking

    • Table GSK Strategic initiatives

    • Table GSK SWOT analysis

    • Table Servier Profiles

    • Table Servier Production, Value, Price, Gross Margin 2014-2019

    • Table Servier Product benchmarking

    • Table Servier Strategic initiatives

    • Table Servier SWOT analysis

    • Table Geropharm Profiles

    • Table Geropharm Production, Value, Price, Gross Margin 2014-2019

    • Table Geropharm Product benchmarking

    • Table Geropharm Strategic initiatives

    • Table Geropharm SWOT analysis

    • Table Sumitomo Dainippon Pharma Profiles

    • Table Sumitomo Dainippon Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Sumitomo Dainippon Pharma Product benchmarking

    • Table Sumitomo Dainippon Pharma Strategic initiatives

    • Table Sumitomo Dainippon Pharma SWOT analysis

    • Table Novo Nordisk Profiles

    • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

    • Table Novo Nordisk Product benchmarking

    • Table Novo Nordisk Strategic initiatives

    • Table Novo Nordisk SWOT analysis

    • Table Takeda Profiles

    • Table Takeda Production, Value, Price, Gross Margin 2014-2019

    • Table Takeda Product benchmarking

    • Table Takeda Strategic initiatives

    • Table Takeda SWOT analysis

    • Table Uni-Bio Science Group Profiles

    • Table Uni-Bio Science Group Production, Value, Price, Gross Margin 2014-2019

    • Table Uni-Bio Science Group Product benchmarking

    • Table Uni-Bio Science Group Strategic initiatives

    • Table Uni-Bio Science Group SWOT analysis

    • Table Merck Profiles

    • Table Merck Production, Value, Price, Gross Margin 2014-2019

    • Table Merck Product benchmarking

    • Table Merck Strategic initiatives

    • Table Merck SWOT analysis

    • Table Emisphere Profiles

    • Table Emisphere Production, Value, Price, Gross Margin 2014-2019

    • Table Emisphere Product benchmarking

    • Table Emisphere Strategic initiatives

    • Table Emisphere SWOT analysis

    • Table Intarcia Therapeutics Profiles

    • Table Intarcia Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Intarcia Therapeutics Product benchmarking

    • Table Intarcia Therapeutics Strategic initiatives

    • Table Intarcia Therapeutics SWOT analysis

    • Table Eli Lilly Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lilly Product benchmarking

    • Table Eli Lilly Strategic initiatives

    • Table Eli Lilly SWOT analysis

    • Table 3SBio Profiles

    • Table 3SBio Production, Value, Price, Gross Margin 2014-2019

    • Table 3SBio Product benchmarking

    • Table 3SBio Strategic initiatives

    • Table 3SBio SWOT analysis

    • Table Luye Pharma Group Profiles

    • Table Luye Pharma Group Production, Value, Price, Gross Margin 2014-2019

    • Table Luye Pharma Group Product benchmarking

    • Table Luye Pharma Group Strategic initiatives

    • Table Luye Pharma Group SWOT analysis

    • Table SatRx Profiles

    • Table SatRx Production, Value, Price, Gross Margin 2014-2019

    • Table SatRx Product benchmarking

    • Table SatRx Strategic initiatives

    • Table SatRx SWOT analysis

    • Table Dong-A Pharmaceutical Profiles

    • Table Dong-A Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Dong-A Pharmaceutical Product benchmarking

    • Table Dong-A Pharmaceutical Strategic initiatives

    • Table Dong-A Pharmaceutical SWOT analysis

    • Table Jiangsu Hansoh Pharmaceutical Profiles

    • Table Jiangsu Hansoh Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Jiangsu Hansoh Pharmaceutical Product benchmarking

    • Table Jiangsu Hansoh Pharmaceutical Strategic initiatives

    • Table Jiangsu Hansoh Pharmaceutical SWOT analysis

    • Table Eurofarma Profiles

    • Table Eurofarma Production, Value, Price, Gross Margin 2014-2019

    • Table Eurofarma Product benchmarking

    • Table Eurofarma Strategic initiatives

    • Table Eurofarma SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US